PH1154

About Kripthonite Therapeutics

Kripthonite Therapeutics is pioneering a novel approach to overcome a fundamental challenge in oncology: treatment-resistant hypoxic cancer cells. Its lead asset, PH1154, is a hypoxia-targeting macrocycle (HTMC) that disrupts the unique energy metabolism of oxygen-starved cells, leading to selective cell death. Strong preclinical data, particularly in combination with radiotherapy, demonstrates the potential to significantly improve tumor eradication and survival. The company is a private, preclinical-stage biotech seeking partnerships to advance its program into clinical trials.

Therapeutic Areas